Determination of perhexiline and its metabolite hydroxyperhexiline in human plasma by liquid chromatography/tandem mass spectrometry

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 877, Issue 27, 2009, Pages 3025-3030

  Zhang, Mei ^a   Moore, Grant A ^b   Barclay, Murray L ^a   Begg, Evan J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

Author keywords

Hydroxyperhexiline; LC MS MS; Perhexiline; Plasma

Indexed keywords

CLINICAL PRACTICES; COEFFICIENTS OF VARIATIONS; CONCENTRATION MONITORING; CONCENTRATION RANGES; ELECTROSPRAYS; GENETIC POLYMORPHISMS; GRADIENT ELUTION; HEPATOTOXICITY; HUMAN PLASMAS; HYDROXYPERHEXILINE; INTERNAL STANDARDS; IONISATION; LC-MS/MS; LIMIT OF QUANTIFICATIONS; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PERHEXILINE; POSITIVE MODE; STANDARD CURVES; THERAPEUTIC INDEX;

ACETONITRILE; BIOMOLECULES; ELECTROSPRAY IONIZATION; LIQUIDS; MASS SPECTROMETERS; MASS SPECTROMETRY; METABOLITES; METHANOL; ORGANIC ACIDS; PLASMA (HUMAN); PLASMAS;

METABOLISM;

ACETONITRILE; HYDROXYPERHEXILINE; NORDOXEPIN; PERHEXILINE; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL STRUCTURE; ELECTROSPRAY; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, LIQUID; DOXEPIN; HUMANS; LINEAR MODELS; PERHEXILINE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

ANGINA;

EID: 69749085651     PISSN: 15700232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchromb.2009.07.021     Document Type: Article

References (16)

1. Ashrafian H., Horowitz J.D., and Frenneaux M.P. Cardiovasc. Drug Rev. 25 (2007) 76
2. Sallustio B.C., Westley I.S., and Morris R.G. Br. J. Clin. Pharmacol. 54 (2002) 107
3. Barclay M.L., Sawyers S.M., Begg E.J., Zhang M., Roberts R.L., Kennedy M.A., and Elliott J.M. Pharmacogenetics 13 (2003) 627
4. Singlas E., Goujet M.A., and Simon P. Eur. J. Clin. Pharmacol. 14 (1978) 195
5. Pilcher J., Cooper J.D.H., Turnell D.C., Matenga J., Paul R., and Lockhart J.D.F. Ther. Drug Monit. 7 (1985) 54
6. Horowitz J.D., Sia S.T.B., MacDonald P.S., Goble A.J., and Louis W.J. Int. J. Cardiol. 13 (1986) 219
7. Cooper R.G., Evans D.A., and Whibley E.J. J. Med. Genet. 21 (1984) 27
8. Cooper R.G., Evans D.A., and Price A.H. Eur. J. Clin. Pharmacol. 32 (1987) 569
9. Sørensen L.B., Sørensen R.N., Miners J.O., Somogyi A.A., Grgurinovich N., and Birkett D.J. Br. J. Clin. Pharmacol. 55 (2002) 635
10. Horowitz J.D., Morris P.M., Drummer O.H., Goble A.J., and Louis W.J. J. Pharm. Sci. 70 (1981) 320
11. Grgurinovich N. J. Chromatogr. B 696 (1997) 75
12. Cooper R.G., Harper G., Price A.H., Evans D.A., and Lockhart D. J. Chromatogr. 381 (1986) 305
13. Sallustio B.C., and Morris R.G. Ther. Drug Monit. 21 (1999) 389
14. Beck O., Stephanson N., Morris R.G., Sallustio B.C., and Hjemdahl P. J. Chromatogr. B 805 (2004) 87
15. Matuszewski B.K., Constanzer M.L., and Chavez-Eng C.M. Anal. Chem. 75 (2003) 3019
16. Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), 2001.